Skip to main content

Jakafi Side Effects

Generic name: ruxolitinib

Medically reviewed by Drugs.com. Last updated on Dec 29, 2023.

Note: This document contains side effect information about ruxolitinib. Some dosage forms listed on this page may not apply to the brand name Jakafi.

Applies to ruxolitinib: oral tablet.

Serious side effects of Jakafi

Along with its needed effects, ruxolitinib (the active ingredient contained in Jakafi) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking ruxolitinib:

More common

Less common

Incidence not known

Other side effects of Jakafi

Some side effects of ruxolitinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to ruxolitinib: oral tablet.

Dermatologic

Very common (10% or more): Bruising (up to 23.2%)

Common (1% to 10%): Herpes zoster[Ref]

Gastrointestinal

Common (1% to 10%): Flatulence, gastrointestinal bleeding[Ref]

Genitourinary

Very common (10% or more): Urinary tract infection (up to 14.4%)[Ref]

Hematologic

Very common (10% or more): Anemia (up to 96.1%), thrombocytopenia (up to 69.8%), neutropenia (up to 18.7%)[Ref]

Immunologic

Common (1% to 10%): Tuberculosis

Frequency not reported: Progressive multifocal leukoencephalopathy[Ref]

Metabolic

Very common (10% or more): Hypercholesterolemia (up to 17.4%), weight gain (up to 10%)[Ref]

Nervous system

Very common (10% or more): Dizziness (up to 18.1%), headache (up to 14.8%)

Common (1% to 10%): Intracranial bleeding[Ref]

General

The most common adverse reactions were anemia, thrombocytopenia, bruising, dizziness, and headache.[Ref]

Cardiovascular

Very common (10% or more): Bleeding (up to 32.6%)[Ref]

Hepatic

Very common (10% or more): ALT increased (up to 27.1%), AST increased (up to 19.3%)[Ref]

Frequently asked questions

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Jakafi (ruxolitinib). Incyte Corporation. 2011.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.